Managing Multiple Sclerosis in Pregnancy: 2026 Updates
Managing multiple sclerosis in pregnancy requires a careful balance between maternal health and fetal safety. Neurologists and obstetricians recently published an expert consensus review to update clinical recommendations. Moreover, modern reproductive counseling empowers women to plan pregnancies safely. Therefore, collaborative healthcare models now offer clearer pathways for disease control throughout childbearing years.
Navigating Multiple Sclerosis in Pregnancy and Preconception
Pre-pregnancy planning plays a pivotal role in optimizing clinical outcomes. Specifically, clinicians should evaluate disease stability for at least six to twelve months prior to conception. In addition, healthcare providers must review all disease-modifying therapies (DMTs) well ahead of time. Some medications require strategic washout windows to avoid fetal complications. However, abrupt cessation of certain high-efficacy therapies can trigger rebound inflammatory activity. Consequently, neurologists must personalize therapeutic adjustments based on individualized risk stratification. Furthermore, routine counseling should emphasize folic acid and vitamin D supplementation. As a result, maternal physical wellness and nutritional reserves improve significantly before pregnancy begins.
Maternal and Fetal Outcomes During Gestation
In most instances, multiple sclerosis does not elevate the risk of adverse gestational outcomes. For example, spontaneous abortion rates and congenital malformation risks remain comparable to the general population. Nevertheless, some clinical studies document slightly higher rates of lower birthweight, preterm birth, and operative delivery. Natural immunomodulatory shifts during the second and third trimesters generally suppress MS relapses. Therefore, many pregnant patients experience notable disease stability during late pregnancy. Meanwhile, obstetricians should maintain routine fetal surveillance and manage common symptoms like urinary infections. In addition, multidisciplinary teams ensure maternal mobility and adequate fatigue management during each trimester.
Postpartum Risks and Long-Term Gynecological Care
The postpartum phase represents a period of heightened neurological and psychological vulnerability. In particular, relapse rates frequently surge during the first three months following delivery. Consequently, clinicians must schedule prompt postpartum evaluations to detect disease reactivation early. In addition, healthcare teams must address postpartum depression and fatigue without delay. Breastfeeding provides numerous maternal and infant advantages, and several therapies remain compatible with lactation. Thus, physicians should support breastfeeding while establishing safe medication timelines. Eventually, when childbearing concludes, gynecological care transitions toward monitoring therapy-associated infections and cervical dysplasia risks. Furthermore, doctors must actively manage bone density and cardiovascular health throughout the menopausal transition.
Frequently Asked Questions
Q1: Does multiple sclerosis increase the risk of congenital abnormalities?
No, multiple sclerosis itself does not increase the risk of congenital abnormalities or spontaneous miscarriages. However, certain disease-modifying therapies carry fetal risks and require planned discontinuation before conception.
Q2: Why does relapse risk increase during the postpartum period?
During pregnancy, maternal immune tolerance naturally dampens inflammatory activity. After delivery, immune activity abruptly rebounds, which significantly increases relapse frequency within the first three months postpartum.
Q3: Can women with multiple sclerosis safely breastfeed while taking medications?
Yes, many patients can breastfeed safely. In fact, several disease-modifying therapies, including specific monoclonal antibodies and interferon formulations, demonstrate minimal transfer into breast milk.
References
- Balshi A et al. Management of Multiple Sclerosis During Pregnancy and the Reproductive Years in 2026: An Expert Clinical Review. Am J Obstet Gynecol. 2026 Sep 08. doi: undefined. PMID: 42710796.
- Krajnc N, Bsteh G, Berger T, Mares J, Hartung HP. Monoclonal antibodies in the treatment of relapsing multiple sclerosis: An overview with emphasis on pregnancy, vaccination, and risk management. Neurotherapeutics. 2022;19(3):753-773.
- Dobson R, Rog D, O'Leary C, et al. Revised Association of British Neurologists consensus guidelines for multiple sclerosis in pregnancy. Mult Scler J. 2026.
